Candel Therapeutics (NasdaqGM:CADL) 2025 Conference Transcript

Summary of Candel Therapeutics Conference Call Company Overview - Company: Candel Therapeutics (NasdaqGM:CADL) - Focus: Development of viral immunotherapies for difficult-to-treat cancers, specifically targeting solid tumors [2][3] Key Products CAN-2409 - Type: First-in-class in situ vaccination for solid tumors - Administration: Requires only 2-3 administrations in a patient's lifetime to achieve durable anti-tumor immunity [3][10] - Clinical Trials: - Phase III Trial: Conducted in newly diagnosed localized prostate cancer, meeting primary endpoint with a 30% improvement in disease-free survival [17][18] - Secondary Endpoint: Achieved a 38% improvement in prostate cancer-specific disease-free survival [18] - Pathological Complete Response: 80.4% in CAN-2409 group vs. 63.6% in control group [18] - FDA Designations: Fast-track and orphan drug designations for prostate and pancreatic cancers [3][4] CAN-3110 - Type: Next-generation oncolytic virus targeting recurrent high-grade glioma - Mechanism: Replication-competent herpes simplex virus that selectively replicates in tumor cells [4][26] - Clinical Data: Early results show long-term survival in patients with recurrent glioblastoma, with some surviving over 59 months post-treatment [28][29] Financial Position - Funding: Recently secured a deal with Trinity Capital for up to $130 million to support clinical trials [22] - Equity Deals: Raised funds in December and the first half of the current year [5] Clinical Strategy - Target Population: Focus on patients with intermediate or high-risk prostate cancer who prefer curative options over radical surgery or radiotherapy [11][12] - Trial Design: Randomized controlled trials with a focus on disease-free survival as the primary endpoint [14][20] - Patient Experience: Administration of CAN-2409 is less traumatic than standard biopsies, with most patients reporting it as better tolerated [16][19] Future Plans - BLA Submission: Planned for Q4 next year, with ongoing preparations for commercial manufacturing and pre-commercialization activities [20][21] - Upcoming Trials: Phase III trial for CAN-2409 in non-small cell lung cancer to start in Q2 next year [24][30] - Data Generation: Continued follow-up on prostate cancer trial patients and new data on CAN-3110 expected [30] Important Insights - Market Position: Candel Therapeutics is positioned uniquely in the market with no direct competition in the newly diagnosed localized prostate cancer space [11] - Long-term Survival: Promising data on long-term survival rates in patients treated with CAN-3110, indicating potential for significant advancements in treatment options for glioblastoma [28][29] - Scientific Rigor: Emphasis on independent peer review and collaboration with leading experts in oncology to ensure high-quality research and development [6][30]